PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Summary

To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.

Timeline

Start

2007-09

Primary completion

2011-03

Completion

2011-04

Drugs

Indications